Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ocera Therapeutics, Inc.
The primary objectives of the study were to evaluate the efficacy of OCR-002 for treatment of an acute hepatic encephalopathy (HE) episode in cirrhotic patients requiring hospitalization and the safety and tolerability of OCR-002 in hospitalized cirrhotic patients with an acute episode of HE.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Hospitalized with an acute episode of hepatic encephalopathy as complication of cirrhosis
Elevated venous ammonia
You may not be if
Renal failure with serum creatinine \> 3 mg/dL or need for dialysis
Molecular Adsorbent Recirculation System utilized
Pregnancy or breastfeeding
Clareo Health | Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
